Drug Profile

Rhenium Re 186 etidronate

Alternative Names: Re 186 HEDP

Latest Information Update: 06 Oct 2004

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mallinckrodt Medical
Developer Mallinckrodt Medical; Memorial Sloan-Kettering Cancer Center; University of Cincinnati
Class Heavy metals; Non-opioid analgesics; Radiopharmaceuticals; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer metastases; Cancer pain

Most Recent Events

06 Oct 2004 Discontinued - Clinical-Phase-Unknown for Cancer metastases in United Kingdom (Injection)
06 Oct 2004 Discontinued - Preregistration for Cancer pain in USA (Injection)
01 Feb 2002 A study has been added to the Pain Control therapeutic trials section

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com